Literature DB >> 26171776

Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus.

Laura J Martins1, Pawel Bonczkowski2, Adam M Spivak3, Ward De Spiegelaere2, Camille L Novis1, Ana Beatriz DePaula-Silva1, Eva Malatinkova2, Wim Trypsteen2, Alberto Bosque1, Linos Vanderkerckhove2, Vicente Planelles1.   

Abstract

HIV-1 latently infected cells in vivo can be found in extremely low frequencies. Therefore, in vitro cell culture models have been used extensively for the study of HIV-1 latency. Often, these in vitro systems utilize defective viruses. Defective viruses allow for synchronized infections and circumvent the use of antiretrovirals. In addition, replication-defective viruses cause minimal cytopathicity because they fail to spread and usually do not encode env or accessory genes. On the other hand, replication-competent viruses encode all or most viral genes and better recapitulate the nuances of the viral replication cycle. The study of latency with replication-competent viruses requires the use of antiretroviral drugs in culture, and this mirrors the use of antiretroviral treatment (ART) in vivo. We describe a model that utilizes cultured central memory CD4(+) T cells and replication-competent HIV-1. This method generates latently infected cells that can be reactivated using latency reversing agents in the presence of antiretroviral drugs. We also describe a method for the removal of productively infected cells prior to viral reactivation, which takes advantage of the downregulation of CD4 by HIV-1, and the use of a GFP-encoding virus for increased throughput.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26171776      PMCID: PMC4761834          DOI: 10.1089/aid.2015.0106

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  47 in total

1.  Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu.

Authors:  Ankur H Shah; Bharatwaj Sowrirajan; Zachary B Davis; Jeffrey P Ward; Edward M Campbell; Vicente Planelles; Edward Barker
Journal:  Cell Host Microbe       Date:  2010-11-18       Impact factor: 21.023

2.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

Authors:  K L Collins; B K Chen; S A Kalams; B D Walker; D Baltimore
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

4.  Determinants of the establishment of human immunodeficiency virus type 1 latency.

Authors:  Alexandra Duverger; Jennifer Jones; Jori May; Frederic Bibollet-Ruche; Frederic A Wagner; Randall Q Cron; Olaf Kutsch
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

5.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

6.  Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives.

Authors:  T Haertle; C J Carrera; D B Wasson; L C Sowers; D D Richman; D A Carson
Journal:  J Biol Chem       Date:  1988-04-25       Impact factor: 5.157

7.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Authors:  Hung-Chih Yang; Sifei Xing; Liang Shan; Karen O'Connell; Jason Dinoso; Anding Shen; Yan Zhou; Cynthia K Shrum; Yefei Han; Jun O Liu; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

8.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

Review 9.  Mechanisms of CD4 downregulation by the Nef and Vpu proteins of primate immunodeficiency viruses.

Authors:  O Wolf Lindwasser; Rittik Chaudhuri; Juan S Bonifacino
Journal:  Curr Mol Med       Date:  2007-03       Impact factor: 2.222

10.  HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription.

Authors:  Xavier Contreras; Matjaz Barboric; Tina Lenasi; B Matija Peterlin
Journal:  PLoS Pathog       Date:  2007-10-12       Impact factor: 6.823

View more
  36 in total

1.  HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay.

Authors:  Sara Sunshine; Rory Kirchner; Sami S Amr; Leandra Mansur; Rimma Shakhbatyan; Michelle Kim; Alberto Bosque; Robert F Siliciano; Vicente Planelles; Oliver Hofmann; Shannan Ho Sui; Jonathan Z Li
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

2.  HIV-1 infection renders brain vascular pericytes susceptible to the extracellular glutamate.

Authors:  Dorota Piekna-Przybylska; Kavyasri Nagumotu; Danielle M Reid; Sanjay B Maggirwar
Journal:  J Neurovirol       Date:  2018-11-06       Impact factor: 2.643

Review 3.  Kill: boosting HIV-specific immune responses.

Authors:  Lydie Trautmann
Journal:  Curr Opin HIV AIDS       Date:  2016-07       Impact factor: 4.283

4.  IFI16 Targets the Transcription Factor Sp1 to Suppress HIV-1 Transcription and Latency Reactivation.

Authors:  Dominik Hotter; Matteo Bosso; Kasper L Jønsson; Christian Krapp; Christina M Stürzel; Atze Das; Elisabeth Littwitz-Salomon; Ben Berkhout; Alina Russ; Sabine Wittmann; Thomas Gramberg; Yue Zheng; Laura J Martins; Vicente Planelles; Martin R Jakobsen; Beatrice H Hahn; Ulf Dittmer; Daniel Sauter; Frank Kirchhoff
Journal:  Cell Host Microbe       Date:  2019-06-04       Impact factor: 21.023

5.  Apobec3A maintains HIV-1 latency through recruitment of epigenetic silencing machinery to the long terminal repeat.

Authors:  Manabu Taura; Eric Song; Ya-Chi Ho; Akiko Iwasaki
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-22       Impact factor: 11.205

6.  Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells.

Authors:  Szu-Han Huang; Yanqin Ren; Allison S Thomas; Dora Chan; Stefanie Mueller; Adam R Ward; Shabnum Patel; Catherine M Bollard; Conrad Russell Cruz; Sara Karandish; Ronald Truong; Amanda B Macedo; Alberto Bosque; Colin Kovacs; Erika Benko; Alicja Piechocka-Trocha; Hing Wong; Emily Jeng; Douglas F Nixon; Ya-Chi Ho; Robert F Siliciano; Bruce D Walker; R Brad Jones
Journal:  J Clin Invest       Date:  2018-01-22       Impact factor: 14.808

7.  BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo.

Authors:  Yanqin Ren; Szu Han Huang; Shabnum Patel; Winiffer D Conce Alberto; Dean Magat; Dughan Ahimovic; Amanda B Macedo; Ryan Durga; Dora Chan; Elizabeth Zale; Talia M Mota; Ronald Truong; Thomas Rohwetter; Chase D McCann; Colin M Kovacs; Erika Benko; Avery Wimpelberg; Christopher Cannon; W David Hardy; Alberto Bosque; Catherine M Bollard; R Brad Jones
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

8.  Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus.

Authors:  Amanda B Macedo; Rachel S Resop; Laura J Martins; Matthew A Szaniawski; Eric S Sorensen; Adam M Spivak; Douglas F Nixon; R Brad Jones; Vicente Planelles; Alberto Bosque
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-10       Impact factor: 2.205

9.  Telomere and ATM Dynamics in CD4 T-Cell Depletion in Active and Virus-Suppressed HIV Infections.

Authors:  Sushant Khanal; Qiyuan Tang; Dechao Cao; Juan Zhao; Lam Nhat Nguyen; Oluwayomi Samson Oyedeji; Xindi Dang; Lam Ngoc Thao Nguyen; Madison Schank; Bal Krishna Chand Thakuri; Chinyere Ogbu; Zheng D Morrison; Xiao Y Wu; Zheng Zhang; Qing He; Mohamed El Gazzar; Zhengke Li; Shunbin Ning; Ling Wang; Jonathan P Moorman; Zhi Q Yao
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

10.  Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.

Authors:  Amanda B Macedo; Camille L Novis; Caroline M De Assis; Eric S Sorensen; Paula Moszczynski; Szu-Han Huang; Yanqin Ren; Adam M Spivak; R Brad Jones; Vicente Planelles; Alberto Bosque
Journal:  JCI Insight       Date:  2018-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.